All Stories

  1. C33-16 Identifiable Characteristics of Asthma Patients at Higher Risk for Exacerbation Using Real-World Biomarkers: Insights to Inform Targeted Therapeutic Strategies
  2. Real World Evidence: Burden Of Systemic Corticosteroid Use In Patients With CRSwNP With and Without Asthma Persists Despite Available Biologic Therapies
  3. Achieving health equity in immune disease: leveraging big data and artificial intelligence in an evolving health system landscape
  4. Burden and healthcare resource utilization across asthma severities
  5. Characterizing the burden of CRSwNP in the biologic era
  6. Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK
  7. Epidemiology of Childhood Asthma in the UK
  8. Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis
  9. Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma
  10. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps
  11. Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma
  12. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
  13. Oral corticosteroid (OCS) burden and healthcare resource utilization (HCRU) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who did or did not undergo functional endoscopic sinonasal surgery (FESS) in US real-world practice
  14. The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP
  15. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
  16. Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
  17. Content Validation of Patient-Reported Sleep Measures and Development of a Conceptual Model of Sleep Disturbance in Patients with Moderate-to-Severe, Uncontrolled Asthma
  18. Prevalence and Severity Distribution of Type 2 Inflammation-Related Comorbidities Among Patients with Asthma, Chronic Rhinosinusitis with Nasal Polyps, and Atopic Dermatitis
  19. Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps
  20. Immunolab: Combining targeted real-world data with advanced analytics to generate evidence at scale in immunology
  21. Impact of Baseline Lung Function on Future Exacerbations in Patients with Moderate-to-Severe Asthma
  22. Impact of exacerbations on lung function, resource utilization, and productivity: results from an observational, prospective study in adults with uncontrolled asthma
  23. Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP
  24. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design
  25. Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS ‐24 and SINUS ‐52...
  26. Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
  27. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
  28. Content validity of a newly developed observer-reported measure for pediatric asthma in children aged 2–5 years
  29. Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
  30. Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD): Measurement Properties of Novel Patient-Reported Symptom Measures
  31. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps
  32. Dupilumab Improves Asthma Control, and Allergic Rhinitis-Related Health-Related Quality of Life in Children With Uncontrolled Persistent Asthma With Comorbid Allergic Rhinitis
  33. Dupilumab achieves durable reduction in severity of symptoms rated most important by patients with chronic rhinosinusitis with nasal polyps
  34. Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI ≥30 kg/m2 or weight ≥90 kg: post-hoc analysis of the SINUS-24 and SINUS-52 studies
  35. Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps
  36. Dupilumab reduces asthma disease burden and recurrent SCS use in patients with CRSwNP and coexisting asthma
  37. EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2 patients: the EVEREST Trial
  38. Symptom Free Days In Patients With Severe Chronic Rhinosinusitis with Nasal Polyps Treated with Dupilumab
  39. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies
  40. Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the ph...
  41. Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
  42. Response to the correspondence: “Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma”
  43. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
  44. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma
  45. Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020)
  46. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
  47. Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis
  48. Dupilumab in CRSwNP : Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
  49. Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab
  50. P184 IMPACT OF DUPILUMAB ON SLEEP/FUNCTION SCORES IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
  51. SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
  52. Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
  53. Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma
  54. Effect of dupilumab on improving physical activity in patients with severe asthma
  55. Association Between a Type 2 Inflammatory Disease Burden Score and Outcomes Among Patients with Asthma
  56. Development of Sinonasal Outcome Test (SNOT‐22) Domains in Chronic Rhinosinusitis With Nasal Polyps
  57. Association Between Dupilumab Effect on Nasal Polyp Score and Biomarkers of Type 2 Inflammation in Patients with Chronic Rhinosinusitis with Nasal Polyps in the Phase 3 SINUS-24 and SINUS-52 Trials
  58. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
  59. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
  60. Reducing Fungal Exposure Critical for Treating Rhinosinusitis with or without Polyps [Response to Letter]
  61. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps
  62. Health-Related Quality of Life Impairment Among Patients With Severe Chronic Rhinosinusitis With Nasal Polyps in the SINUS-24 Trial
  63. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis
  64. ASSOCIATION BETWEEN ASTHMA SEVERITY, QUALITY OF LIFE, AND PRODUCTIVITY IN FRANCE, GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM
  65. DUPILUMAB IMPROVES PATIENT-REPORTED BREATHING IN ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA
  66. DUPILUMAB REDUCES SEVERE OUTPATIENT ASTHMA EXACERBATIONS, CUMULATIVE DOSE, AND TOTAL NUMBER OF DAYS OF SYSTEMIC CORTICOSTEROID USE AMONG PATIENTS WITH MODERATE-TO-SEVERE TYPE-2 ASTHMA
  67. PREVALENCE OF ASTHMA IN FRANCE, GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM, BASED ON THE 2018 EUROPEAN NATIONAL HEALTH AND WELLNESS SURVEY
  68. Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis
  69. Effect of Dupilumab on patient-reported breathing and rescue medication use
  70. Dupilumab Improves Asthma Control as Assessed by Total and Individual Item Scores of the 6-Item Asthma Control Questionnaire in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: Pooled Results from the SINUS-24 and SINU...
  71. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis
  72. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma
  73. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
  74. Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis
  75. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP
  76. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD
  77. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma
  78. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history
  79. Dupilumab Improved Asthma Control and Health-Related Quality of Life in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study
  80. Dupilumab Improved Morning and Evening Daily Asthma Symptoms in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study
  81. Dupilumab Improved Asthma Control in Patients With Uncontrolled, Moderate-to-Severe Asthma, Regardless of Exacerbations in the Previous Year
  82. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps
  83. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps
  84. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life
  85. DUPILUMAB IMPROVES ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA, REGARDLESS OF EXACERBATION HISTORY
  86. IMPACT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS ON QUALITY OF LIFE BY SINO-NASAL SURGERY HISTORY
  87. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
  88. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
  89. Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial